News room

Egetis is an innovative and integrated pharmaceutical company, focusing on projects in late-stage development for commercialization for treatments of serious diseases with significant unmet medical needs in the orphan drug segment

Dr Thomas Lönngren nominated as new Chairman of the Board at Egetis Therapeutics

March 26, 2021

Stockholm, Sweden, March 26, 2021. Egetis Therapeutics AB (publ) (ticker: EGTX) today announced that the nomination committee proposes that the former Head of the European Medicines Agency (EMA), Dr Thomas Lönngren, is appointed Chairman of the Board of Directors of Egetis Therapeutics. He replaces Håkan Åström, who has served as Chairman since 2011. The decision will be taken at the Annual General Meeting on April 29, and a notice will be sent out separately.

Dr Lönngren has extensive experience as a senior executive within the life science community, serving as Deputy General Director of the Swedish Medical Product Agency (MPA) up to 2000 followed by EMA, where he led the agency as Executive Director between 2001 and 2010. At EMA, he oversaw the implementation of several EU regulatory reforms, including the Orphan drug legislation, Pediatrics legislation, revised Pharmacovigilance legislation and Advanced Therapies legislation.
He also has a vast experience as a board member and scientific adviser in the global biotech and medtech industry, with a specific focus on drug regulation, approval, market access, management, strategy and leadership.
Dr Lönngren has a Master of Science degree in social and regulatory pharmacy, University of Uppsala, and a degree in Pharmacy, Pharmaceutical Faculty, University of Uppsala. Dr Lönngren has received a number of Honors and Awards for his contributions in the medicine world and among them holds an Honorary Doctorate from the University of Uppsala, Sweden and is an Honorary Member of the Royal Pharmaceutical Society of Great Britain and an Honorary Fellow of the Royal College of Physicians in Great Britain.
“We are incredibly happy to be able attract such a senior professional and life science executive as Thomas to the company. With our strategic focus on late-stage orphan development, registration and commercialization, we believe that his experience, expertise and networks will significantly benefit the company. The current Chairman Håkan Åström, who has been with the company for ten years, has declined re-election due to personal reasons, and I want to thank Håkan for the tremendous, skilled and invaluable work he has put into the business over this period”, said Kennet Rooth, Chairman of the nomination committee.
“I am very excited to join Egetis Therapeutics in their continued journey to build an orphan focused company. Egetis has a highly competent team and two late-stage assets that look very promising and could reach the market already in a few years time. I look forward to working together with CEO Nicklas Westerholm and his team and the rest of the Board to achieve this goal and further grow and develop the company over the coming years”, said Dr Thomas Lönngren.



Contact us

Address: Klara Norra Kyrkogata 26, SE 111 22 Stockholm, Sweden

Phone: +46 8 679 72 10